The Effects of Combined Estrogen and Fluocalcic Effervescent Therapy on the Bone Metabolism in Surgically Menopausal Women with Osteopenia.
- Author:
Heung Yeol KIM
1
;
Hye Eun PARK
;
Wan Kyu EO
Author Information
1. Department of Obstetrics and Gynecology, College of Medicine, Kosin University, Busan, Korea. hykyale@yahoo.com
- Publication Type:Clinical Trial ; Original Article ; Randomized Controlled Trial
- Keywords:
Osteopenia;
Conjugated equine estrogen;
Fluocalcic
- MeSH:
Alkaline Phosphatase;
Biomarkers;
Bone Diseases, Metabolic*;
Estrogens*;
Female;
Humans;
Metabolism*;
Osteocalcin;
Prospective Studies
- From:Korean Journal of Obstetrics and Gynecology
2006;49(4):874-881
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: To evaluate the effects of combined estrogen and fluocalcic therapy on the bone metabolism in the surgicalyl menopausal women with osteopenia. METHODS: This prospective randomized clinical trial examined the effects of conjugated equine estrogen and fluocalcic in combination and separately, on BMD in 200 women with low bone mass. Treatment included 0.3 mg conjugated equine estrogen (CEE) (Group I), 0.625 mg CEE (Group II), 0.3 mg CEE plus fluocalcic (Group III), and 0.625 mg CEE plus fluocalcic (Group IV) for 12 months. Biochemical markers of bone turnover were also measured every six months. RESULTS: Urinary deoxypyridinoline in Group III and Group IV decreased signifiantly at 12 months of treatment (p<0.005). Serum osteocalcin and total alkaline phosphatase decreased slightly during the treatment in all groups but statistical significance was not foundsignificantly. CONCLUSION: The combined treatment with conjugated equine estrogen and fluocalcic is more effective in surgically menopausal women with osteopenia by decreasing bone biochemical marker.
